Venlafaxine is used to treat depression and generalized anxiety disorder (GAD), excessive tension and difficulty to control worry, social anxiety disorder (excessive fear of interacting with other people, interfering with normal life) and panic disorder (sudden and unexpected attacks of intense fear). Venlafaxine belongs to a class of antidepressants called selective serotonin and norepinephrine reuptake inhibitors (SSNRIs). Venlafaxine works by increasing the amounts of serotonin and norepinephrine, two natural substances in the brain that help maintain mental balance.
The side effects that venlafaxine can generate are: asthenia, chills, fatigue, hypertension, vasodilation, palpitations, decreased appetite, constipation, nausea, vomiting, xerostomia, dyspepsia, hypercholesterolemia, weight loss, abnormal dreams, decreased libido, dizziness, dry mouth, headache, hypertonia, insomnia, nervousness, paresthesia, sedation, drowsiness, tremor, confusion, depersonalization, yawning, sweating, accommodation abnormalities, mydriasis, visual disturbances, tinnitus, ejaculation/abnormal orgasms in males, anorgasmia , erectile dysfunction, urination disorders, menstrual disorders, dysuria. Venlafaxine is contraindicated in concomitant prescription with MAOI antidepressants. Do not start treatment with venlafaxine until 14 days after stopping treatment with MAOIs and stop treatment with venlafaxine for at least 7 days before starting treatment with MAOIs.
The Brand names of venlafaxine are: Arafaxina Retard ®, Conervin Retard ®, Dislaven Retard ®, Dobupal ®, Flaxen ®, Levest ®, Vandral ®, Venlabrain Retard ®, Venlamylan ®, Venlapine ®, Zarelis ®.
There are certain genes that present variants in the general population and their presence is associated with a better response to venlafaxine in those patients carriers of them. This is the case of variants in the HTR2 and PACAP genes that we study in the technical report.
GENE OR REGION STUDIED